tetano
Editor, Senior Moderator
Infect Dis Rep
. 2022 Dec 9;14(6):996-1003.
doi: 10.3390/idr14060099.
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
Kana Fujimoto[SUP] 1 [/SUP], Satoru Mutsuo[SUP] 2 [/SUP], Yuto Yasuda[SUP] 1 [/SUP], Soichi Arasawa[SUP] 3 [/SUP], Noriyuki Tashima[SUP] 1 [/SUP], Daisuke Iwashima[SUP] 1 [/SUP], Ken-Ichi Takahashi[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The neutralizing ability of sotrovimab and casirivimab/imdevimab against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is attenuated in the subvariant BA.5. However, the efficacy of sotrovimab in the clinical setting remains to be investigated.
Methods: Patients admitted to Kishiwada City Hospital with COVID-19 delta, omicron BA.1, or BA.5 subvariants were evaluated retrospectively for serum SARS-CoV-2 S and N antibody levels using the Elecsys Anti-SARS-CoV-2 assay.
Results: In patients with COVID-19 during the BA.5 wave of the COVID-19 pandemic, anti-SARS-CoV-2 S antibody titers (median [interquartile range]) increased from 2154.0 (864.0-6669.3) U/mL on day 0 to 21,371.0 (19,656.3-32,225.0) U/mL on day 3 in the group treated with sotrovimab (N = 40) and were significantly higher than in the group treated with remdesivir plus dexamethasone plus baricitinib (p < 0.001).
Conclusion: Treatment with sotrovimab could prevent severe disease in high-risk patients infected with SARS-CoV-2 subvariant BA.5.
Keywords: COVID-19; S antibody; SARS-CoV-2; remdesivir; sotrovimab.
. 2022 Dec 9;14(6):996-1003.
doi: 10.3390/idr14060099.
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
Kana Fujimoto[SUP] 1 [/SUP], Satoru Mutsuo[SUP] 2 [/SUP], Yuto Yasuda[SUP] 1 [/SUP], Soichi Arasawa[SUP] 3 [/SUP], Noriyuki Tashima[SUP] 1 [/SUP], Daisuke Iwashima[SUP] 1 [/SUP], Ken-Ichi Takahashi[SUP] 1 [/SUP]
Affiliations
- PMID: 36547245
- DOI: 10.3390/idr14060099
Abstract
Background: The neutralizing ability of sotrovimab and casirivimab/imdevimab against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is attenuated in the subvariant BA.5. However, the efficacy of sotrovimab in the clinical setting remains to be investigated.
Methods: Patients admitted to Kishiwada City Hospital with COVID-19 delta, omicron BA.1, or BA.5 subvariants were evaluated retrospectively for serum SARS-CoV-2 S and N antibody levels using the Elecsys Anti-SARS-CoV-2 assay.
Results: In patients with COVID-19 during the BA.5 wave of the COVID-19 pandemic, anti-SARS-CoV-2 S antibody titers (median [interquartile range]) increased from 2154.0 (864.0-6669.3) U/mL on day 0 to 21,371.0 (19,656.3-32,225.0) U/mL on day 3 in the group treated with sotrovimab (N = 40) and were significantly higher than in the group treated with remdesivir plus dexamethasone plus baricitinib (p < 0.001).
Conclusion: Treatment with sotrovimab could prevent severe disease in high-risk patients infected with SARS-CoV-2 subvariant BA.5.
Keywords: COVID-19; S antibody; SARS-CoV-2; remdesivir; sotrovimab.